Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
Where are you with wearable devices? Sporting an Apple Watch or a Fitbit right now? When was the last time you looked at it? When patients ask you about a new device they saw on the internet, do you do some intel?
Cardiologists discuss the questions and concerns swirling around the thriving wearables market as patients strap on a variety of smart devices and expect their physicians to catch up.
Atrial fibrillation patients with coronary artery disease pose a delicate balancing act for physicians. A growing awareness of bleeding vs. ischemic risks could soon lead to a steadier therapeutic response.
